SML0650

Risedronate sodium

≥97% (HPLC)

• Sinónimos: P,P′-[1-Hydroxy-2-(3-pyridinyl)ethylidene]bis-phosphonic acid sodium, Sodium risedronate, [1-Hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt
• Fórmula empírica (notación de Hill): C₇H₁₀NO₇P₂ · Na
• Número CAS: 115436-72-1
• Peso molecular: 305.09
• UNSPSC Code: 41106300
• NACRES: NA.77
• Assay: ≥97% (HPLC)
• Form: powder

Propiedades

• Quality Segment: 100
• assay: ≥97% (HPLC)
• form: powder
• color: white to beige
• solubility: H₂O: 5 mg/mL, clear (warmed)
• storage temp.: room temp
• SMILES string: [Na+].[P](=O)([O-])(O)[C@]([P](=O)(O)O)(O)Cc1cnccc1
• InChI: 1S/C7H11NO7P2.Na/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);/q;+1/p-1
• InChI key: DRFDPXKCEWYIAW-UHFFFAOYSA-M

Descripción

Biochem/physiol Actions

Risedronate sodium is a bisphosphonate bone resorption inhibitor.

Risedronate sodium is a bisphosphonate bone resorption inhibitor. It has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent and is an inhibitor of farnesyl diphosphate (FPP) synthase, which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. Risedronate sodium has been used to treat postmenopausal osteoporosis and Paget′s disease.

Información de seguridad

• pictograms: GHS07
• signalword: Warning
• hcodes: H302 + H312 + H332
• pcodes: P261 - P264 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312
• Hazard Classifications: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable